Browsing Tag
Biogen Inc.
2 posts
Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025
Find out how Eisai and Biogen's LEQEMBI may slow Alzheimer’s by over 8 years in early-stage patients, as new CTAD 2025 data reveals long-term benefits.
FDA accepts application for LEQEMBI subcutaneous dosing: A step forward in Alzheimer’s care
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has accepted…